CD38 and Miyoshi myopathy: A preclinical study in 2023 designed ionizable LNPs coated with anti-CD38 antibodies; these targeted LNPs delivered siRNA to bone-marrow-resident MM cells, reduced cell viability in vitro and improved tumor control in xenograft models, highlighting that bone-marrow targeting is possible but still limited to preclinical model [5] (Figure 5).